Air Liquide: Healthcare: development in specialty ingredients with the acquisition of BiotechMarine

  Air Liquide: Healthcare: development in specialty ingredients with the
  acquisition of BiotechMarine

Business Wire

PARIS -- January 7, 2013

Regulatory News:

Air Liquide (Paris:AI) reinforces its activity in healthcare specialty
ingredients with the acquisition of BiotechMarine by its subsidiary SEPPIC.
BiotechMarine is a leading player in the design and marketing of active
ingredients for the global cosmetics industry.

A subsidiary of the Roullier Group, BiotechMarine is a company that
specialises in the design and marketing of bio-based, cosmetic active
ingredients made fromalgae. BiotechMarine is basedin the west of France, in
the town of Pontrieux, and has 35employees.

Since its creation in 1988, BiotechMarine has been recognised for its
know-how. This company boasts a complete range of natural active ingredients
sold all over the world, which are used in cosmetic products in particular.

The acquisition of BiotechMarine will provide SEPPIC, a subsidiary in
AirLiquide's Healthcare Business Line, with complementary expertise in marine
biotechnologies and plant cell culture. SEPPIC thus widens its product
portfolio with a complete range of active ingredients from marine
biodiversity.

Pascal Vinet, Vice President, Healthcare Global Operations and member of the
Group’s Executive Committee, commented: "We are delighted to welcome these new
employees to the Group. With this acquisition Air Liquide intends to reinforce
its position in the field of healthcare specialty ingredients. The
complementarity of BiotechMarine and SEPPIC allows us to widen our know-how
and continue the development of this activity. Health is one of the Group's
growth drivers."

AirLiquide's Healthcare Business line

AirLiquide's Healthcare World Business Line provides medical gases, home
healthcare services, hygiene products, medical equipments, and specialty
ingredients.

In 2011, it served over 6,000hospitals and 700,000 patients at home around
the world.

In 2011, the Group Healthcare Business Line published €2,076million in
revenues generated by 9,300employees.

In 2012, SEPPIC (specialty  ingredients) joined the Healthcare activity.

SEPPIC in brief

A subsidiary of the Air Liquide Group, within the Healthcare activity, SEPPIC
develops and markets a wide range of healthcare specialty ingredients –
excipients and active ingredients – intended for the personal care,
pharmaceutical and vaccine markets.

Present in over 80 countries through its subsidiaries and its network of
distributors, SEPPIC employs over 550 people around the world, including 100
researchers.

Air Liquide is the world leader in gases for industry, health and the
environment, and is present in 80countries with 46,200employees. Oxygen,
nitrogen, hydrogen and rare gases have been at the core of AirLiquide’s
activities since its creation in 1902. Using these molecules, Air Liquide
continuously reinvents its business, anticipating the needs of current and
future markets. The Group innovates to enable progress, to achieve dynamic
growth and a consistent performance.

Innovative technologies that curb polluting emissions, lower industry’s energy
use, recover and reuse natural resources or develop the energies of tomorrow,
such as hydrogen, biofuels or photovoltaic energy… Oxygen for hospitals, home
healthcare, fighting nosocomial infections… AirLiquide combines many products
and technologies to develop valuable applications and services not only for
its customers but also for society.

A partner for the long term, Air Liquide relies on employee commitment,
customer trust and shareholder support to pursue its vision of sustainable,
competitive growth. The diversity of AirLiquide’s teams, businesses, markets
and geographic presence provides a solid and sustainable base for its
development and strengthens its ability to push back its own limits, conquer
new territories and build its future.

Air Liquide explores the best that air can offer to preserve life, staying
true to its sustainable development approach. In 2011, the Group’s revenues
amounted to €14.5billion, of which more than 80% were generated outside
France. AirLiquide is listed on the Paris Euronext stock exchange
(compartment A) and is a member of the CAC 40 and Dow Jones Euro Stoxx 50
indexes.

                              www.airliquide.com
                    Follow us on Twitter @AirLiquideGroup

Contact:

Group Communications
Corinne Estrade-Bordry, + 33 (0)1 40 62 51 31
Garance Bertrand, + 33 (0)1 40 62 59 62
or
Investor Relations
Virginia Jeanson, +33 (0) 1 40 62 57 37
Annie Fournier, +33 (0) 1 40 62 57 18
or
Air Liquide Healthcare
Communications
Muriel Doucet, + 33 (0)1 49 69 46 46